Disclosure Of Entity's Operating Segments [Text Block]

Xbrane Biopharma - Filing #689990

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31
Disclosure of entity's operating segments [text block]	—	—	—	—	—	—
Disclosure of operating segments [text block]	—	—	—	—	—	—
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Revenue	—	57 618 SEK	—	—	10 709 SEK	—
Tax expense (income)	—	– SEK	—	—	– SEK	—
Profit (loss) before tax	—	168 513 SEK	—	—	183 226 SEK	—
Profit (loss) from continuing operations	—	168 513 SEK	—	—	183 226 SEK	—
Profit (loss)	—	172 513 SEK	172 513 SEK	—	188 376 SEK	188 376 SEK
Assets	690 515 SEK	—	—	688 427 SEK	—	—
Liabilities	265 626 SEK	—	—	256 686 SEK	—	—
Cash flows from (used in) operating activities	—	193 918 SEK	—	—	219 610 SEK	—
Cash flows from (used in) investing activities	—	60 125 SEK	—	—	77 350 SEK	—
Cash flows from (used in) financing activities	—	148 864 SEK	—	—	349 365 SEK	—
Disclosure of products and services [text block]	—	—	—	—	—	—
Disclosure of products and services [abstract]
Disclosure of products and services [line items]
Disclosure of geographical areas [text block]	—	—	—	—	—	—
Disclosure of geographical areas [abstract]
Disclosure of geographical areas [line items]
Disclosure of major customers [text block]	—	—	—	—	—	—
Disclosure of major customers [abstract]
Disclosure of major customers [line items]